COMPARATIVE ANALYSIS OF EFFECTIVENESS OF ANTIVIRAL THERAPY IN CHRONIC HUMAN HERPESVIRUS 6 TYPE INFECTION

Abstract

Introduction. In recent years human-6 herpes virus (HHV-6) has become the most commonly detected virus in peripheral blood, saliva and cerebrospinal fluid, both in asymptomatic infections and in diseases potentially associated with HHV-6. Today, no antiviral drug has been officially approved for the treatment of HHV-6. Materials and methods. 57 patients with chronic HHV-6 infection were examined (mean age 33.34 ± 1.86 years). Patients were divided into three groups for different treatment regimens: 1 group (12 patients) received therapy with Famvir; Group 2 (16 patients) received Valcite; Group 3 (29 patients) - Ingaron. All patients were determined by the number of copies of HHV-6 DNA by PCR in saliva samples before and after the therapy. Results. None of the patient groups received negative PCR results after treatment. In groups of patients after valcyte therapy and therapy with Ingaron there is a significant decrease in the number of copies of HHV-6 DNA. The severity of complaints after therapy was also analyzed. Significant therapeutic effect a month after therapy showed Ingaron, to a slightly lesser extent - Valcite. The worst result was obtained in the group of patients receiving famvir.